Abstract
Since the introduction of biologic therapies that target tumor necrosis factor (TNF), short-term and long-term outlooks for many patients with rheumatoid arthritis have greatly improved. Not all patients, however, respond to therapy with these agents. Furthermore, despite favorable overall profiles for safety and tolerability, some concerns remain in this regard. Following the emergence of next-generation biologic agents with new targets, a key question for clinicians concerns the relative efficacy and safety of the different biologic therapies. A study by Schiff et al. directly compared the biologic T-cell costimulation blocker abatacept and the anti-TNF agent infliximab. The results of the 6-month, placebo-controlled trial demonstrated a similar efficacy for both drugs; however, in the 6-month treatment extension period, outcomes of efficacy differed in favor of abatacept. Overall, abatacept had a relatively more-acceptable safety and tolerability profile compared to infliximab.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dixon WG et al. (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54: 2368–2376
Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13–20
Steinbrook R (2008) Saying no isn't NICE—the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 359: 1977–1981
Schiff M et al. (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67: 1096–1103
Kremer JM et al. (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144: 865–876
Genovese MC et al. (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67: 547–554
Rahman MU et al. (2007) Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 66: 1233–1238
Author information
Authors and Affiliations
Ethics declarations
Competing interests
PC Taylor has received speakers' honoraria from Bristol–Myers Squibb and grant/research support from Schering–Plough.
Rights and permissions
About this article
Cite this article
Taylor, P. How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA?. Nat Rev Rheumatol 5, 126–127 (2009). https://doi.org/10.1038/ncprheum1022
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum1022
